"The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.
HER2 is a protein involved in normal cell growth. It is foun"...
Patients should understand that there is a risk of irreversible myocardial damage associated with treatment with ELLENCE, as well as a risk of treatment-related leukemia.
Patients should consult their physician if vomiting, dehydration, fever, evidence of infection, symptoms of CHF, or injection-site pain occurs following therapy with ELLENCE.
Advise patients that their urine may appear red for 1 to 2 days after administration of ELLENCE and that they should not be alarmed.
Because ELLENCE may induce chromosomal damage in sperm, advise men undergoing treatment with ELLENCE to use effective contraceptive methods. Women treated with ELLENCE may develop irreversible amenorrhea, or premature menopause.
This product's label may have been updated. For current full prescribing information, please visit www.pfizer.com.
Last reviewed on RxList: 12/30/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Ellence Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find support and advances in treatment.